Compounds for the treatment of auricular fibrillation
AssigneeProyecto De Biomedicina Cima, S.L.
InventorsRafael Franco Fernández, Franciso Ciruela Alférez, Carmen Lluís Biset, Christa Müller, Joan Cinca Cuscullola, Leif Hove-Madsen
Life of this patent
Estimating the term…
Abstract
Adenosine A2A receptor antagonists are useful for the preparation of medicaments against atrial fibrillation in mammals, including humans. It has been found that the adenosine A2A receptor is present in human atrial cardiomyocytes and participates in the pathological mechanisms underlying atrial fibrillation. An advantage of using A2A antagonists over other agents known in the art is that the A2A antagonists specifically target patients with atrial fibrillation.
Claims8
A method of treating atrial fibrillation in a mammal, comprising administering to said mammal an effective amount of a selective adenosine A2A receptor antagonist, wherein the selective adenosine A2A receptor antagonist is a compound selected from the group consisting of:
A method of treating atrial fibrillation in a mammal, comprising administering to said mammal an effective amount of a selective adenosine A2A receptor antagonist, wherein the selective adenosine A2A receptor antagonist is a compound selected from the group consisting of:
Dependencies are inferred from the claim text.